Dissection of the host-pathogen interaction in human tuberculosis using a bioengineered 3-dimensional model

eLife

Volumn 6, Issue , 2017, Pages

  Tezera, Liku B ^a   Bielecka, Magdalena K ^a   Chancellor, Andrew ^a   Reichmann, Michaela T ^a   Shammari, Basim Al ^b   Brace, Patience ^a   Batty, Alex ^a   Tocheva, Annie ^a   Jogai, Sanjay ^a   Marshall, Ben G ^a   Tebruegge, Marc ^a   Jayasinghe, Suwan N ^c   Mansour, Salah ^a,d   Elkington, Paul T ^a,d  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b KING ABDULLAH INTERNATIONAL MEDICAL RESEARCH CENTER   (Saudi Arabia)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORDANE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; ALGINIC ACID; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; CCL2 PROTEIN, HUMAN; CFP-10 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; COLLAGEN; CXCL10 PROTEIN, HUMAN; ESAT-6 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; GLUCURONIC ACID; HEXURONIC ACID; IL1B PROTEIN, HUMAN; MICROSPHERE; PROSTAGLANDIN E2;

APOPTOSIS; ARTICLE; CELL AGGREGATION; CELL ENCAPSULATION; CELL ISOLATION; CELL MEDIATED CYTOTOXICITY; CELL VIABILITY; COLLAGEN DEGRADATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; BIOLOGICAL MODEL; BIOSYNTHESIS; CHEMISTRY; COCULTURE; DRUG EFFECTS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; IMMUNOLOGY; MICROBIOLOGY; MONONUCLEAR CELL; MULTICELLULAR SPHEROID; PATHOGENICITY; PHYSIOLOGY; SECRETION (PROCESS); VIRULENCE;

ALGINATES; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CHEMOKINE CCL2; CHEMOKINE CXCL10; COCULTURE TECHNIQUES; COLLAGEN; DINOPROSTONE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GLUCURONIC ACID; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEXURONIC ACIDS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MICROSPHERES; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; SPHEROIDS, CELLULAR; VIRULENCE;

EID: 85010653758     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.21283     Document Type: Article

References (73)

1. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P. 2011. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nature Medicine 17:189-194. doi: 10.1038/nm.2285
2. Al Shammari B, Shiomi T, Tezera L, Bielecka MK, Workman V, Sathyamoorthy T, Mauri F, Jayasinghe SN, Robertson BD, D’Armiento J, Friedland JS, Elkington PT. 2015. The extracellular matrix regulates granuloma necrosis in tuberculosis. Journal of Infectious Diseases 212:463-473. doi: 10.1093/infdis/jiv076
3. Andreu N, Zelmer A, Fletcher T, Elkington PT, Ward TH, Ripoll J, Parish T, Bancroft GJ, Schaible U, Robertson BD, Wiles S. 2010. Optimisation of bioluminescent reporters for use with mycobacteria. PLoS One 5:e10777. doi: 10.1371/journal.pone.0010777
4. Barrila J, Radtke AL, Crabbé A, Sarker SF, Herbst-Kralovetz MM, Ott CM, Nickerson CA. 2010. Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions. Nature Reviews Microbiology 8:791-801. doi: 10.1038/nrmicro2423
5. Benam KH, Dauth S, Hassell B, Herland A, Jain A, Jang KJ, Karalis K, Kim HJ, MacQueen L, Mahmoodian R, Musah S, Torisawa YS, van der Meer AD, Villenave R, Yadid M, Parker KK, Ingber DE. 2015. Engineered in vitro disease models. Annual Review of Pathology: Mechanisms of Disease 10:195-262. doi: 10.1146/annurevpathol-012414-040418
6. Brites D, Gagneux S. 2015. Co-evolution of Mycobacterium tuberculosis and Homo sapiens. Immunological Reviews 264:6-24. doi: 10.1111/imr.12264
7. Buchheit CL, Rayavarapu RR, Schafer ZT. 2012. The regulation of cancer cell death and metabolism by extracellular matrix attachment. Seminars in Cell & Developmental Biology 23:402-411. doi: 10.1016/j.semcdb.2012.04.007
8. Calderon VE, Valbuena G, Goez Y, Judy BM, Huante MB, Sutjita P, Johnston RK, Estes DM, Hunter RL, Actor JK, Cirillo JD, Endsley JJ. 2013. A humanized mouse model of tuberculosis. PLoS One 8:e63331. doi: 10.1371/journal.pone.0063331
9. Cambier CJ, Falkow S, Ramakrishnan L. 2014. Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell 159:1497-1509. doi: 10.1016/j.cell.2014.11.024
10. Carroll P, Schreuder LJ, Muwanguzi-Karugaba J, Wiles S, Robertson BD, Ripoll J, Ward TH, Bancroft GJ, Schaible UE, Parish T. 2010. Sensitive detection of gene expression in mycobacteria under replicating and nonreplicating conditions using optimized far-red reporters. PLoS One 5:e9823. doi: 10.1371/journal.pone.0009823
11. Chakraborty S, Ji H, Kabadi AM, Gersbach CA, Christoforou N, Leong KW. 2014. A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem Cell Reports 3:940-947. doi: 10.1016/j.stemcr.2014.09.013
12. Cheng F, Pekkonen P, Laurinavicius S, Sugiyama N, Henderson S, Gunther T, Rantanen V, Kaivanto E, Aavikko M, Sarek G, Hautaniemi S, Biberfeld P, Aaltonen L, Grundhoff A, Boshoff C, Alitalo K, Lehti K, Ojala PM. 2011. KSHV-initiated notch activation leads to membrane-type-1 matrix metalloproteinase-dependent lymphatic endothelial-to-mesenchymal transition. Cell Host & Microbe 10:577-590. doi: 10.1016/j.chom.2011.10.011
13. Cliff JM, Kaufmann SH, McShane H, van Helden P, O’Garra A. 2015. The human immune response to tuberculosis and its treatment: a view from the blood. Immunological Reviews 264:88-102. doi: 10.1111/imr.12269
14. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S, Kremer K, Ernst JD, Gagneux S. 2010. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nature Genetics 42:498-503. doi: 10.1038/ng.590
15. Comstock GW, Livesay VT, Woolpert SF. 1974. The prognosis of a positive tuberculin reaction in childhood and adolescence. American Journal of Epidemiology 99:131-138
16. Coscolla M, Copin R, Sutherland J, Gehre F, de Jong B, Owolabi O, Mbayo G, Giardina F, Ernst JD, Gagneux S. 2015. M. tuberculosis T cell epitope analysis reveals paucity of antigenic variation and identifies rare variable TB antigens. Cell Host & Microbe 18:538-548. doi: 10.1016/j.chom.2015.10.008
17. Crowle AJ, Elkins N. 1990. Relative permissiveness of macrophages from black and white people for virulent tubercle bacilli. Infection and Immunity 58:632-638
18. del Corral H, París SC, Marín ND, Marín DM, López L, Henao HM, Martínez T, Villa L, Barrera LF, Ortiz BL, Ramírez ME, Montes CJ, Oquendo MC, Arango LM, Riaño F, Aguirre C, Bustamante A, Belisle JT, Dobos K, Mejía GI, et al. 2009. IFNgamma response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 4:e8257. doi: 10.1371/journal.pone.0008257
19. Douvas GS, Looker DL, Vatter AE, Crowle AJ. 1985. Gamma interferon activates human macrophages to become tumoricidal and leishmanicidal but enhances replication of macrophage-associated mycobacteria. Infection and Immunity 50:1-8
20. Egen JG, Rothfuchs AG, Feng CG, Winter N, Sher A, Germain RN, Macrophage GRN. 2008. Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas. Immunity 28:271-284. doi: 10.1016/j.immuni.2007.12.010
21. Elkington PT, D’Armiento JM, Friedland JS. 2011. Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Science Translational Medicine 3:71ps6. doi: 10.1126/scitranslmed.3001847
22. Elkington PT, Friedland JS. 2015. Permutations of time and place in tuberculosis. The Lancet Infectious Diseases 15:1357-1360. doi: 10.1016/S1473-3099(15)00135-8
23. Elkington PT, Green JA, Friedland JS. 2006. Filter sterilization of highly infectious samples to prevent false negative analysis of matrix metalloproteinase activity. Journal of Immunological Methods 309:115-119. doi: 10.1016/j.jim.2005.11.01
24. Flynn JL, Chan J. 2001. Immunology of tuberculosis. Annual Review of Immunology 19:93-129. doi: 10.1146/annurev.immunol.19.1.93
25. Gideon HP, Phuah J, Myers AJ, Bryson BD, Rodgers MA, Coleman MT, Maiello P, Rutledge T, Marino S, Fortune SM, Kirschner DE, Lin PL, Flynn JL. 2015. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLoS Pathogens 11:e1004603. doi: 10.1371/journal.ppat.1004603
26. Guirado E, Schlesinger LS. 2013. Modeling the mycobacterium tuberculosis granuloma - the critical battlefield in host immunity and disease. Frontiers in Immunology 4:98. doi: 10.3389/fimmu.2013.00098
27. Hawn TR, Matheson AI, Maley SN, Vandal O. 2013. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiology and Molecular Biology Reviews 77:608-627. doi: 10.1128/MMBR.00032-13
28. Hawn TR, Shah JA, Kalman D. 2015. New tricks for old dogs: countering antibiotic resistance in tuberculosis with host-directed therapeutics. Immunological Reviews 264:344-362. doi: 10.1111/imr.12255
29. Heuts F, Gavier-Widén D, Carow B, Juarez J, Wigzell H, Rottenberg ME. 2013. CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. PNAS 110:6482-6487. doi: 10.1073/pnas.1219985110
30. Higuchi K, Harada N, Fukazawa K, Mori T. 2008. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. Tuberculosis 88:244-248. doi: 10.1016/j.tube.2007.11.009
31. Horsburgh CR, Barry CE, Lange C. 2015. Treatment of Tuberculosis. New England Journal of Medicine 373: 2149-2160. doi: 10.1056/NEJMra1413919
32. Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE. 2015. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunological Reviews 264:74-87. doi: 10.1111/imr.12274
33. Kapoor N, Pawar S, Sirakova TD, Deb C, Warren WL, Kolattukudy PE. 2013. Human granuloma in vitro model, for TB dormancy and resuscitation. PLoS One 8:e53657. doi: 10.1371/journal.pone.0053657
34. Karp CL, Wilson CB, Stuart LM. 2015. Tuberculosis vaccines: barriers and prospects on the quest for a transformative tool. Immunological Reviews 264:363-381. doi: 10.1111/imr.12270
35. Kaufmann SH, Dorhoi A. 2013. Inflammation in tuberculosis: interactions, imbalances and interventions. Current Opinion in Immunology 25:441-449. doi: 10.1016/j.coi.2013.05.005
36. Kimmey JM, Huynh JP, Weiss LA, Park S, Kambal A, Debnath J, Virgin HW, Stallings CL. 2015. Unique role for ATG5 in neutrophil-mediated immunopathology during M. tuberculosis infection. Nature 528:565-569. doi: 10.1038/nature16451
37. Lay G, Poquet Y, Salek-Peyron P, Puissegur MP, Botanch C, Bon H, Levillain F, Duteyrat JL, Emile JF, Altare F. 2007. Langhans giant cells from M. tuberculosis-induced human granulomas cannot mediate mycobacterial uptake. The Journal of Pathology 211:76-85. doi: 10.1002/path.2092
38. Lindestam Arlehamn CS, Paul S, Mele F, Huang C, Greenbaum JA, Vita R, Sidney J, Peters B, Sallusto F, Sette A. 2015. Immunological consequences of intragenus conservation of Mycobacterium tuberculosis T-cell epitopes. PNAS 112:E147-E155. doi: 10.1073/pnas.1416537112
39. Luabeya AK, Kagina BM, Tameris MD, Geldenhuys H, Hoff ST, Shi Z, Kromann I, Hatherill M, Mahomed H, Hanekom WA, Andersen P, Scriba TJ, Schoeman E, Krohn C, Day CL, Africa H, Makhethe L, Smit E, Brown Y, Suliman S, et al. 2015. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults. Vaccine 33:4130-4140. doi: 10.1016/j.vaccine.2015.06.051
40. Majlessi L, Prados-Rosales R, Casadevall A, Brosch R. 2015. Release of mycobacterial antigens. Immunological Reviews 264:25-45. doi: 10.1111/imr.12251
41. Mansour S, Tocheva AS, Sanderson JP, Goulston LM, Platten H, Serhal L, Parsons C, Edwards MH, Woelk CH, Elkington PT, Elliott T, Cooper C, Edwards CJ, Gadola SD. 2015. Structural and functional changes of the invariant NKT clonal repertoire in early rheumatoid arthritis. The Journal of Immunology 195:5582-5591. doi: 10.4049/jimmunol.1501092
42. Marakalala MJ, Raju RM, Sharma K, Zhang YJ, Eugenin EA, Prideaux B, Daudelin IB, Chen PY, Booty MG, Kim JH, Eum SY, Via LE, Behar SM, Barry CE, Mann M, Dartois V, Rubin EJ. 2016. Inflammatory signaling in human tuberculosis granulomas is spatially organized. Nature Medicine 22:531-538. doi: 10.1038/nm.4073
43. Mattila JT, Ojo OO, Kepka-Lenhart D, Marino S, Kim JH, Eum SY, Via LE, Barry CE, Klein E, Kirschner DE, Morris SM, Lin PL, Flynn JL. 2013. Microenvironments in tuberculous granulomas are delineated by distinct populations of macrophage subsets and expression of nitric oxide synthase and arginase isoforms. The Journal of Immunology 191:773-784. doi: 10.4049/jimmunol.1300113
44. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, Derrick SC, Shi R, Kumar NP, Wei W, Yuan X, Zhang G, Cai Y, Babu S, Catalfamo M, Salazar AM, Via LE, Barry CE, Sher A. 2014. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511:99-103. doi: 10.1038/nature13489
45. Moreira-Teixeira L, Sousa J, McNab FW, Torrado E, Cardoso F, Machado H, Castro F, Cardoso V, Gaifem J, Wu X, Appelberg R, Castro AG, O’Garra A, Saraiva M. 2016. Type I IFN inhibits alternative macrophage activation during Mycobacterium tuberculosis infection and leads to enhanced protection in the absence of IFN-g signaling. The Journal of Immunology 197:4714-4726. doi: 10.4049/jimmunol.1600584
46. Mueller-Klieser W. 1997. Three-dimensional cell cultures: from molecular mechanisms to clinical applications. The American Journal of Physiology 273:C1109-C1123.
47. Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, Dièye S, Dieye TN, Esmail H, Goliath R, Huygen K, January V, Ndiaye I, Oni T, Raine M, Romano M, Satti I, Sutton S, Thiam A, Wilkinson KA, Mboup S, et al. 2015. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine 3:190-200. doi: 10.1016/S2213-2600(15)00037-5
48. Nouailles G, Dorhoi A, Koch M, Zerrahn J, Weiner J, Faé KC, Arrey F, Kuhlmann S, Bandermann S, Loewe D, Mollenkopf HJ, Vogelzang A, Meyer-Schwesinger C, Mittrucker HW, McEwen G, Kaufmann SH. 2014. CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. Journal of Clinical Investigation 124:1268-1282. doi: 10.1172/JCI72030
49. Nunes-Alves C, Booty MG, Carpenter SM, Jayaraman P, Rothchild AC, Behar SM. 2014. In search of a new paradigm for protective immunity to TB. Nature Reviews Microbiology 12:289-299. doi: 10.1038/nrmicro3230
50. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. 2013. The immune response in tuberculosis. Annual Review of Immunology 31:475-527. doi: 10.1146/annurev-immunol-032712-095939
51. O’Kane CM, Elkington PT, Jones MD, Caviedes L, Tovar M, Gilman RH, Stamp G, Friedland JS. 2010. STAT3, p38 MAPK, and NF-kappaB drive unopposed monocyte-dependent fibroblast MMP-1 secretion in tuberculosis. American Journal of Respiratory Cell and Molecular Biology 43:465-474. doi: 10.1165/rcmb.2009-0211OC
52. Orme IM, Robinson RT, Cooper AM. 2015. The balance between protective and pathogenic immune responses in the TB-infected lung. Nature Immunology 16:57-63. doi: 10.1038/ni.3048
53. Pampaloni F, Reynaud EG, Stelzer EH. 2007. The third dimension bridges the gap between cell culture and live tissue. Nature Reviews Molecular Cell Biology 8:839-845. doi: 10.1038/nrm2236
54. Parasa VR, Rahman MJ, Ngyuen Hoang AT, Svensson M, Brighenti S, Lerm M. 2014. Modeling Mycobacterium tuberculosis early granuloma formation in experimental human lung tissue. Disease Models & Mechanisms 7: 281-288. doi: 10.1242/dmm.013854
55. Parker MW, Rossi D, Peterson M, Smith K, Sikstrom K, White ES, Connett JE, Henke CA, Larsson O, Bitterman PB. 2014. Fibrotic extracellular matrix activates a profibrotic positive feedback loop. Journal of Clinical Investigation 124:1622-1635. doi: 10.1172/JCI71386
56. Philips JA, Ernst JD. 2012. Tuberculosis pathogenesis and immunity. Annual Review of Pathology: Mechanisms of Disease 7:353-384. doi: 10.1146/annurev-pathol-011811-132458
57. Puissegur MP, Botanch C, Duteyrat JL, Delsol G, Caratero C, Altare F. 2004. An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cellular Microbiology 6:423-433. doi: 10.1111/j.1462-5822.2004.00371.x
58. Reikerå O, Helle A, Krohn CD, Brox JI. 2009. Effectsofhigh-dosecorticosteroidsonpost-traumatic inflammatory mediators. Inflammation Research 58:891-897. doi: 10.1007/s00011-009-0061-3
59. Rook GA, Steele J, Ainsworth M, Champion BR. 1986. Activation of macrophages to inhibit proliferation of Mycobacterium tuberculosis: comparison of the effects of recombinant gamma-interferon on human monocytes and murine peritoneal macrophages. Immunology 59:333-338
60. Russell DG. 2011. Mycobacterium tuberculosis and the intimate discourse of a chronic infection. Immunological Reviews 240:252-268. doi: 10.1111/j.1600-065X.2010.00984.x
61. Schwartz MA, Chen CS. 2013. Cell biology. Deconstructing dimensionality. Science 339:402-404. doi: 10.1126/science.1233814
62. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, et al. 2013. Genomic responses in mouse models poorly mimic human inflammatory diseases. PNAS 110:3507-3512. doi: 10.1073/pnas.1222878110
63. Snijder B, Sacher R, Ramo P, Damm EM, Liberali P, Pelkmans L. 2009. Population context determines cell-to-cell variability in Endocytosis and virus infection. Nature 461:520-523. doi: 10.1038/nature08282
64. Sorokin L. 2010. The impact of the extracellular matrix on inflammation. Nature Reviews Immunology 10:712-723. doi: 10.1038/nri2852
65. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H, MVA85A 020 Trial Study Team. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. The Lancet 381:1021-1028. doi: 10.1016/S0140-6736(13)60177-4
66. Van Rhijn I, Moody DB, Rhijn V I, Moody DB. 2015. CD1 and mycobacterial lipids activate human T cells. Immunological Reviews 264:138-153. doi: 10.1111/imr.12253
67. Vogt G, Nathan C. 2011. In vitro differentiation of human macrophages with enhanced antimycobacterial activity. Journal of Clinical Investigation 121:3889-3901. doi: 10.1172/JCI57235
68. Warner DF, Mizrahi V. 2014. Shortening treatment for tuberculosis-to basics. New England Journal of Medicine 371:1642-1643. doi: 10.1056/NEJMe1410977
69. Workman VL, Tezera LB, Elkington PT, Jayasinghe SN. 2014. Controlled generation of microspheres incorporating extracellular matrix fibrils for Three-Dimensional cell culture. Advanced Functional Materials 24: 2648-2657. doi: 10.1002/adfm.201303891
70. Wolfl M, Greenberg PD. 2014. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nature Protocols 9:950-966. doi: 10.1038/nprot.2014.064
71. Yamada KM, Cukierman E. 2007. Modeling tissue morphogenesis and cancer in 3D. Cell 130:601-610. doi: 10.1016/j.cell.2007.08.006
72. Young D. 2009. Animal models of tuberculosis. European Journal of Immunology 39:2011-2014. doi: 10.1002/eji.200939542
73. Zumla A, Maeurer M, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, et al. 2015. Towards host-directed therapies for tuberculosis. Nature Reviews Drug Discovery 14: 511-512. doi: 10.1038/nrd4696